Cite
HARVARD Citation
Poller, B. et al. (2019). Fevipiprant has a low risk of influencing co-medication pharmacokinetics: Impact on simvastatin and rosuvastatin in different SLCO1B1 genotypes. Pulmonary pharmacology & therapeutics. p. . [Online].